Filing Flows › Guardant Health (GH) › Q2 2026 › vs Q1 2026
Guardant Health (GH) Q2 2026 vs Q1 2026 (quarter over quarter)
Guardant Health's revenue rose $33.3M (+11%) from $302M in Q1 2026 to $335M in Q2 2026. The biggest changes: Oncology +$14.2M (+7%); Screening +$11.3M (+27%); Biopharma and data +$8.0M (+15%).
Guardant Health, Q2 2026: revenue $335M (+44% year over year), operating margin -38.5%, net loss $120M, operating cash flow −$57.8M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Oncology | $219M | $205M | $14.2M | +7% |
| Biopharma and data | $60.9M | $53.0M | $8.0M | +15% |
| Screening | $52.9M | $41.6M | $11.3M | +27% |
| Licensing and other | $2.1M | $2.1M | −$84K | -4% |
| Revenue | $335M | $302M | $33.3M | +11% |
| Other income, net | $9.2M | $9.6M | −$486K | -5% |
| Net loss | $120M | $112M | $8.1M | +7% |
| Costs & expenses | $464M | $423M | $40.9M | +10% |
| Operating costs | $464M | $423M | $41.1M | +10% |
| Income tax | $185K | $372K | −$187K | -50% |
| Cost of revenue | $116M | $105M | $11.0M | +11% |
| Research & development | $96.5M | $91.0M | $5.5M | +6% |
| Sales & marketing | $190M | $169M | $20.8M | +12% |
| General & admin | $61.7M | $57.9M | $3.7M | +6% |
| Operating cash sources | $125M | $123M | $2.4M | +2% |
| Depreciation & amortization | $9.6M | $9.4M | $119K | +1% |
| Share-based compensation | $57.7M | $47.6M | $10.1M | +21% |
| Cash used in operations | $57.8M | $65.6M | −$7.8M | -12% |
| Net loss absorbed | $120M | $112M | $8.1M | +7% |
| Working capital & other | $4.9M | $10.6M | −$5.7M | -54% |
Questions
How much did Guardant Health's revenue grow quarter over quarter in Q2 2026?
Guardant Health's revenue rose $33.3M (+11%) from $302M in Q1 2026 to $335M in Q2 2026.
What drove Guardant Health's revenue change in Q2 2026?
Oncology +$14.2M (+7%); Screening +$11.3M (+27%); Biopharma and data +$8.0M (+15%).